On the mechanism of plasmin-induced platelet aggregation: Implications of the dual role of granule ADP

Biochemical Pharmacology

Volumn 59, Issue 11, 2000, Pages 1345-1355

  Ishii Watabe, Akiko ^a   Uchida, Eriko ^a   Mizuguchi, Hiroyuki ^a   Hayakawa, Takao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

ADP; Aggregation; Plasmin; Platelet; Potentiation; Receptor

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ADENOSINE DIPHOSPHATE; ADRENALIN; ALPHA ,BETA METHYLENE ADENOSINE 5' TRIPHOSPHATE; APYRASE; C 69931; CLODRONIC ACID; N6 [2 (METHYLTHIO) ETHYL] 2 (3,3,3 TRIFLUOROPROPYL)THIO 5' ADENYLIC ACID; PLASMIN; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; DEGRANULATION; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENYLATE CYCLASE; APYRASE; BLOOD PLATELETS; CALCIUM; CELL DEGRANULATION; DRUG INTERACTIONS; EPINEPHRINE; FIBRINOLYTIC AGENTS; HUMANS; LIGANDS; MEMBRANE PROTEINS; PLASMIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2;

EID: 0034213826     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00279-3     Document Type: Article

References (33)

1. Collen D., Lijnen H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 78:1991;3114-3124.
2. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;33-42.
3. Gram J., Jespersen J., Kluft C., Rijken D.C. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand. 221:1987;149-153.
4. Puri R.N., Hu C.J., Matsueda R., Umeyama H., Colman R.W. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide. Thromb Res. 65:1992;533-547.
5. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost. 43:1980;77-89.
6. Califf R.M., Fortin D.F., Tenaglia A.N., Sane D.C. Clinical risks of thrombolytic therapy. Am J Cardiol. 69:1992;12a-20a.
7. Schafer A.I., Maas A.K., Ware J.A., Johnson P.C., Rittenhouse S.E., Salzman E.W. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest. 78:1986;73-79.
8. Rabhi Sabile S., Pidard D. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors. Thromb Haemost. 73:1995;693-701.
9. Rabhi Sabile S., de Romeuf C., Pidard D. On the mechanism of plasmin-induced aggregation of human platelets Implication of secreted von Willebrand factor . Thromb Haemost. 79:1998;1191-1198.
10. Watabe A., Ohta M., Matsuyama N., Mizuno K., el Borai N., Tanimoto T., Kawanishi T., Hayakawa T. Characterization of plasmin-induced platelet aggregation. Res Commun Mol Pathol Pharmacol. 96:1997;341-352.
11. Boarder M.R., Hourani S.M.D. The regulation of vascular function by P2 receptors Multiple sites and multiple receptors . Trends Pharmacol Sci. 19:1998;99-107.
12. Gayle R.B. III, Maliszewski C.R., Gimpel S.D., Schoenborn M.A., Caspary R.G., Richards C., Brasel K., Price V., Drosopoulos J.H.F., Islam N., Alyonycheva T.N., Broekman M.J., Marcus A.J. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest. 101:1998;1851-1859.
13. Puri R. ADP-induced platelet aggregation and inhibition of adenylyl cyclase activity stimulated by prostaglandins. Biochem Pharmacol. 57:1999;851-859.
14. Geiger J., Honig Liedl P., Schanzenbacher P., Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol. 351:1998;235-246.
15. Daniel J.L., Dangelmaier C., Jin J., Ashby B., Smith J.B., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 273:1998;2024-2029.
16. Jin J., Daniel J.L., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 273:1998;2030-2034.
17. Jin J., Kunapuli S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA. 95:1998;8070-8074.
18. Savi P., Beauverger P., Labouret C., Delfaud M., Salel V., Kaghad M., Herbert J.M. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 422:1998;291-295.
19. Ingall A.H., Dixon J., Bailey A., Coombs M.E., Cox D., McInally J.I., Hunt S.F., Kindon N.D., Teobald B.J., Willis P.A., Humphries R.G., Leff P., Clegg J.A., Smith J.A., Tomlinson W. Antagonists of the platelet P2T receptor A novel approach to antithrombotic therapy . J Med Chem. 42:1999;213-220.
20. i indicators with greatly improved fluorescence properties. J Biol Chem. 260:1985;3440-3450.
21. Motulsky H.J., Insel P.A. Adrenergic receptors in man Direct identification, physiologic regulation, and clinical alterations . N Engl J Med. 307:1982;18-29.
22. 2-adrenergic receptor with guanine nucleotide regulatory proteins in phospholipid vesicles. J Biol Chem. 261:1986;3901-3909.
23. McNicol A. Functional responses Secretion . Watson S.P., Authi K.S. Platelets. 1995;13-19 IRL Press, New York.
24. Puri R.N., Zhou F.X., Colman R.F., Colman R.W. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain. Am J Physiol. 259:1990;C862-C868.
25. Penny W.F., Ware J.A. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood. 79:1992;91-98.
26. Nakamura K., Kimura M., Fenton J.W. II, Andersen T.T., Aviv A. Duality of plasmin effect on cytosolic free calcium in human platelets. Am J Physiol. 268:1995;C958-C967.
27. 2+ mobilization induced by collagen, but not thrombin or ADP, are inhibited by phenylarsine oxide. Br J Haematol. 88:1994;830-838.
28. i. J Biol Chem. 265:1990;11044-11049.
29. o by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity. J Biol Chem. 265:1990;14176-14186.
30. Kaczmarek E., Koziak K., Sevigny J., Siegel J.B., Anrather J., Beaudoin A.R., Bach F.H., Robson S.C. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem. 271:1996;33116-33122.
31. Marcus A.J., Broekman M.J., Drosopoulos J.H., Islam N., Alyonycheva T.N., Safier L.B., Hajjar K.A., Posnett D.N., Schoenborn M.A., Schooley K.A., Gayle R.B., Maliszewski C.R. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 99:1997;1351-1360.
32. Bach F.H., Robson S.C., Winkler H., Ferran C., Stuhlmeier K.M., Wrighton C.J., Hancock W.W. Barriers to xenotransplantation. Nat Med. 1:1995;869-873.
33. Robson S.C., Candinas D., Siegel J.B., Kopp C., Millan M., Hancock W.W., Bach F.H. Potential mechanism of abnormal thromboregulation in xenograft rejection Loss of ecto-ATPases upon endothelial cell activation . Transplant Proc. 28:1996;536.